Clinical Trials List
2025-01-01 - 2031-12-31
Phase III
Recruiting12
ICD-10G30.0
Alzheimer's disease with early onset
ICD-10G30.1
Alzheimer's disease with late onset
ICD-10G30.8
Other Alzheimer's disease
ICD-10G30.9
Alzheimer's disease, unspecified
ICD-9331.0
Alzheimer's disease
A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline
-
Trial Applicant
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Sponsor
Eli Lilly and Company
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Kuan-Fei Chen 無
- Ching-Hua Lu Lu 無
- 程康倫 無
- Yi-Ting Hsu 無
- Yi-Chien Yang 無
- 林欽揚 無
- Hui-Chun Huang 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 張維紘 無
- Wei-Pin Hong 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chun-Yu Chen 無
- 蔡孟儒 無
- 林詠萱 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Pin-Kuei Fu 無
- 劉柏伸 無
- 陳虹潔 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 莊宜芳 無
- YEN-HSIANG HUANG 無
- 賴資賢 無
- 李佳穎 無
- 甄瑞興 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 杜振豐 無
- CHIUNG-MEI CHEN 無
- 張國軒 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
measured by CDR
Inclution Criteria
● Has a reliable trial partner familiar with the participant's overall function and behavior, such as daily activities and cognitive abilities.
● At screening, the participant's reading, vision, and hearing are sufficient for neuropsychological testing.
● Mini-Mental State Examination (MMSE) score of 27 at the first follow-up visit.
● Functional Activities Questionnaire (FAQ) score < 6 at the first follow-up visit.
● If currently receiving medication for symptom treatment of Alzheimer's disease (e.g., cholinergic inhibitors), the dosage has been consistently stable for at least 30 days prior to the first follow-up visit and is expected to remain stable throughout the trial.
Exclusion Criteria
● Currently suffering from a serious or unstable illness, or a condition that may interfere with the analysis of this trial.
● A history of cancer with a high risk of relapse that would prevent completion of the trial.
● A history of clinically significant multiple drug allergies or severe drug allergies, marked atopic anaphylaxis, or severe post-treatment anaphylaxis.
● Having any contraindications to MRI.
● Laboratory test results or other abnormalities determined by the investigator.
● Amyloid-related imaging abnormalities confirmed by central laboratory-interpreted MRI at the time of screening—edema/effusion (ARIA-E), >4 sites of cerebral microbleeds, any surface hemoglobin deposits, any major hemorrhage, or severe white matter disease.
Previous or Current Therapy
● Previous passive anti-amyloid immunotherapy within <5 half-lives prior to the first follow-up visit.
● Previous active anti-Aβ immunotherapy in any other trial.
The Estimated Number of Participants
-
Taiwan
35 participants
-
Global
1400 participants
